The purpose of this investigation was to enhance the dissolution rate of loratadine using polyethylene glycol 6000 (PEG) solid dispersions (SDs). The solubility behavior of loratadine in the presence of polyethylene glycol 4000 and polyethylene glycol 6000 in water showed linear increase with increasing concentrations of PEG, indicating AL type solubility diagrams. SDs of loratadine with PEG 6000 were prepared at 1 : 1, 1 : 3, 1 : 5, 1 : 7 and 1 : 9 ratios by the solvent evaporation method. Solid dispersions were characterized for drug content, dissolution behavior and for physicochemical characteristics. The dissolution rate of loratadine was enhanced rapidly with increasing concentrations of PEG 6000 in SDs. Fourier transform infrared (FTIR) studies showed the stability of loratadine and the absence of a well-defined loratadine - PEG 6000 interaction. Differential scanning calorimetry (DSC) and X-ray powder diffractometry (XRD) studies revealed the amorphous state of loratadine in SDs of loratadine with PEG 6000 which was_x000D_ further confirmed from scanning electron microscopy (SEM) studies. The flow properties of the blend, physical characteristics and disintegration time of the tablets formulated indicated that PEG 6000 SD can be used to formulate fast release loratadine tablets.

Loratadine Phase Solubility Polyethylene Glycol Solid Dispersion

Horter D, Dressman JB, Adv. Drug Deliv. Rev., 25, 3 (1997)
Franco M, Trapani G, Latrofa A, Tullio C, Provenzano MR, Serra M, Muggironi M, Biggio G, Liso G, Int. J. Pharm., 225, 63 (2001)
Ghorab MK, Adeyeye MC, Pharm. Dev. Technol., 6, 305 (2001)
Nokhodchi A, Javadzadeh Y, Reza M, Barzegar jalali M, J.Pharm. Pharm. Sci., 8, 18 (2005)
Kim CK, Cho YJ, Gao ZG, J. Control. Rel., 70, 149 (2001)
Elaine ML, Gary GL, Eugene RC, Eur. J. Pharm. Sci., 18, 113 (2003)
Serajuddin ATM, J. Pharm. Sci., 88, 88 (1999)
Leuner C, Dressman J, Eur. J. Pharm. Biopharm., 50, 47 (2000)
Teofilo V, Bruno S, Paulo C, Drug Discov. Today., 12, 1068 (2007)
Khan GM, Zhu JB, Drug Dev. Ind. Pharm., 24, 455 (1998)
Kearney AS, Gabriel DW, Mehta SC, Radebaugh GW, Int. J. Pharm., 104, 169 (1994)
Potluri RHK, Bandari S, Jukanti R, Veerareddy PR, Arch.Pharm. Res., 34, 51 (2011)
Okonogi S, Oguchi T, Yonemochi E, Puttipipatkhachorn S, Yamamoto K, Int. J. Pharm., 156, 175 (1997)
Frances C, Veiga MD, Espanol OM, Cadorniga R, Int. J.Pharm., 77, 193 (1991)
Ter Laak AM, Tsai RS, Donne-Op den Kelder GM, Carrupt PA, Testa B , Timmerman H, Eur. J. Pharm. Sci., 2, 373 (1994)
Ter Laak AM, Bijloo GJ, Fischer MJE, Donne-Op den Kelder GM, Wilting J, Timmerman H, Eur. J. Pharm. Sci., 4, 307 (1996)
Seghal A, J. Srivastava and V. K. Arora, Patent No. WO 2004082589A2 (2004)
Abdel-Rahman SI, Ahmad SM, Samy IM, Badawy AMM, Ethiop. Pharm. J., 17, 1 (1999)
Omar L, El-Barghouthi MI, Masoud NA, Abdoh AA, Al Omari MM, Zughul MB, Badwan AA, J. Solution. Chem., 36, 605 (2007)
Damian F, Blaton N, Naesens L, Balzarini J, Kinget R, Augustinjns P, Mooter GV, Eur. J. Pharm. Sci., 10, 311 (2000)
Staniforth JN, Pharmaceutics, in: M. E. Aulton (Ed.), The Science Dosage Form Design, Churchill, Livingstone, 610 (1988)
Carr RL, Chem. Eng., 72, 163 (1965)
Khan KA, J. Pharm. Pharmacol., 27, 48 (1975)
Barzegar-Jalali M, Maleki N, Garjani A, Khandar AA, Haji-Hosseinloo M, Jabbari R, Dastmalchi S, Drug Dev. Ind. Pharm., 28, 681 (2002)
Zerrouk N, Chemtob C, Arnaud P, Toscani S, Dugue J, Int. J.Pharm., 225, 49 (2001)
Mukne AP, Nagarsenker MS, AAPS PharmSciTech., 5, 19 (2004)
Shah JC, Chen JR, Chow D, Int. J. Pharm., 113, 103 (1995)
Serajuddin ATM, Sheen PC, Augustine MA, J. Pharm.Sci., 79, 463 (1990)
Tang L, Khan SU, Muhammad NA, Pharm. Dev. Technol., 6, 531 (2001)
Khan N, Craig DQM, J. Control. Rel., 93, 355 (2003)
Hancock BC, Zographi G, J. Pharm. Sci., 86, 1 (1997)
Shin SC, Kim J, Int. J. Pharm., 251, 79 (2003)
Walker GM, Holland CR, Ahmad MMN, Craig DQM, Chem. Eng. Sci., 60(14), 3867 (2005)